Form D · Biotechnology
PATH EX, Inc.
Houston, TX · CIK 0001705898
Offering snapshot reported May 9, 2025 · SEC filing
- Reported sold
- $8.21M Offering amount: $8.21M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 25, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 9, 2025 | Initial | $8,208,948 | No comparison | 14 | SEC filing |
| May 5, 2017 | Initial | $100,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-545680
Total amount sold includes $2,967,808.21 of cancellation of indebtedness to purchase Preferred Stock and $5,100,000 of new cash to purchase convertible promissory notes and warrants to purchase preferred stock.
Source: Form D, filed May 9, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Burbank | Director |
| Ehsan Jabbarzadeh | Director |
| Sinead Miller | Director, Executive |
| Sindead Miller | Director, Executive |
| Alex Wieseler | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2450 Holcombe Blvd., Ste J
Houston, TX, 77021
Houston, TX, 77021